We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SIGA Technologies Inc | NASDAQ:SIGA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.39 | 10.41 | 10.67 | 0 | 01:00:00 |
|
x
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
For the Quarterly Period Ended September 30, 2019
|
|
Or
|
¨
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
For the transition period from ________ to ___________
|
Delaware
|
13-3864870
|
(State or other jurisdiction of
|
(IRS Employer Identification. No.)
|
incorporation or organization)
|
|
|
|
31 East 62nd Street
|
10065
|
New York, NY
|
(zip code)
|
(Address of principal executive offices)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
common stock, $.0001 par value
|
SIGA
|
The Nasdaq Global Market
|
Large accelerated filer ¨
|
|
Accelerated filer x
|
Non-accelerated filer ¨
|
|
Smaller reporting company ¨
|
|
|
Emerging growth company ¨
|
|
|
|
Page No.
|
|
|
|
|
|
September 30, 2019
|
|
December 31, 2018
|
||||
ASSETS
|
|
|
|
||||
Current assets
|
|
|
|
||||
Cash and cash equivalents
|
$
|
78,095,231
|
|
|
$
|
100,652,809
|
|
Restricted cash, short-term
|
11,053,200
|
|
|
11,452,078
|
|
||
Accounts receivable
|
3,217,701
|
|
|
1,959,133
|
|
||
Inventory
|
3,931,161
|
|
|
2,908,210
|
|
||
Prepaid expenses and other current assets
|
2,324,439
|
|
|
4,317,615
|
|
||
Total current assets
|
98,621,732
|
|
|
121,289,845
|
|
||
|
|
|
|
||||
Property, plant and equipment, net
|
2,749,758
|
|
|
171,274
|
|
||
Restricted cash, long-term
|
87,079,574
|
|
|
68,292,023
|
|
||
Deferred tax assets, net
|
12,799,060
|
|
|
11,733,385
|
|
||
Goodwill
|
898,334
|
|
|
898,334
|
|
||
Other assets
|
862,979
|
|
|
1,058,880
|
|
||
Total assets
|
$
|
203,011,437
|
|
|
$
|
203,443,741
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
Current liabilities
|
|
|
|
||||
Accounts payable
|
$
|
2,251,814
|
|
|
$
|
1,688,488
|
|
Accrued expenses and other current liabilities
|
9,544,060
|
|
|
9,648,917
|
|
||
Total current liabilities
|
11,795,874
|
|
|
11,337,405
|
|
||
Warrant liability
|
6,433,427
|
|
|
12,380,939
|
|
||
Other liabilities
|
3,004,313
|
|
|
1,263,113
|
|
||
Long-term debt
|
78,911,307
|
|
|
75,547,597
|
|
||
Total liabilities
|
100,144,921
|
|
|
100,529,054
|
|
||
Commitments and contingencies
|
|
|
|
||||
Stockholders’ equity
|
|
|
|
||||
Common stock ($.0001 par value, 600,000,000 shares authorized, 81,074,280 and 80,763,350 issued and outstanding at September 30, 2019, and December 31, 2018, respectively)
|
8,107
|
|
|
8,076
|
|
||
Additional paid-in capital
|
221,388,212
|
|
|
218,697,872
|
|
||
Accumulated deficit
|
(118,529,803
|
)
|
|
(115,791,261
|
)
|
||
Total stockholders’ equity
|
102,866,516
|
|
|
102,914,687
|
|
||
Total liabilities and stockholders’ equity
|
$
|
203,011,437
|
|
|
$
|
203,443,741
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Revenues
|
|
|
|
|
|
|
|
||||||||
Product sales and supportive services
|
$
|
3,915,335
|
|
|
$
|
468,865,229
|
|
|
$
|
11,057,735
|
|
|
$
|
468,865,229
|
|
Research and development
|
4,195,989
|
|
|
2,210,095
|
|
|
11,420,284
|
|
|
6,619,245
|
|
||||
Total revenues
|
8,111,324
|
|
|
471,075,324
|
|
|
22,478,019
|
|
|
475,484,474
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating expenses
|
|
|
|
|
|
|
|
||||||||
Cost of sales and supportive services
|
737,274
|
|
|
95,166,271
|
|
|
1,652,641
|
|
|
95,166,271
|
|
||||
Selling, general and administrative
|
3,196,370
|
|
|
3,114,678
|
|
|
9,755,165
|
|
|
9,051,617
|
|
||||
Research and development
|
3,343,521
|
|
|
3,723,198
|
|
|
9,379,125
|
|
|
10,043,205
|
|
||||
Patent expenses
|
173,580
|
|
|
186,028
|
|
|
543,806
|
|
|
582,833
|
|
||||
Total operating expenses
|
7,450,745
|
|
|
102,190,175
|
|
|
21,330,737
|
|
|
114,843,926
|
|
||||
Operating income
|
660,579
|
|
|
368,885,149
|
|
|
1,147,282
|
|
|
360,640,548
|
|
||||
Gain (loss) from change in fair value of warrant liability
|
981,923
|
|
|
(2,328,674
|
)
|
|
4,774,711
|
|
|
(5,271,503
|
)
|
||||
Interest expense
|
(3,971,952
|
)
|
|
(3,924,124
|
)
|
|
(11,871,401
|
)
|
|
(11,516,103
|
)
|
||||
Other income, net
|
759,881
|
|
|
5,067
|
|
|
2,233,588
|
|
|
151,454
|
|
||||
(Loss)/income before income taxes
|
(1,569,569
|
)
|
|
362,637,418
|
|
|
(3,715,820
|
)
|
|
344,004,396
|
|
||||
Benefit for income taxes
|
363,742
|
|
|
25,412,995
|
|
|
977,278
|
|
|
25,412,498
|
|
||||
Net and comprehensive (loss)/income
|
$
|
(1,205,827
|
)
|
|
$
|
388,050,413
|
|
|
$
|
(2,738,542
|
)
|
|
$
|
369,416,894
|
|
Basic (loss)/income per share
|
$
|
(0.01
|
)
|
|
$
|
4.85
|
|
|
$
|
(0.03
|
)
|
|
$
|
4.64
|
|
Diluted (loss)/income per share
|
$
|
(0.03
|
)
|
|
$
|
4.71
|
|
|
$
|
(0.09
|
)
|
|
$
|
4.53
|
|
Weighted average shares outstanding: basic
|
81,064,927
|
|
|
80,023,044
|
|
|
80,988,813
|
|
|
79,650,373
|
|
||||
Weighted average shares outstanding: diluted
|
82,181,858
|
|
|
82,929,476
|
|
|
82,148,333
|
|
|
82,744,227
|
|
|
|
Nine months ended September 30,
|
||||||
|
|
2019
|
|
2018
|
||||
Cash flows from operating activities:
|
|
|
|
|
||||
Net (loss)/income
|
|
$
|
(2,738,542
|
)
|
|
$
|
369,416,894
|
|
Adjustments to reconcile net (loss)/income to net cash used in operating activities:
|
|
|
|
|
||||
Depreciation and other amortization
|
|
395,540
|
|
|
48,639
|
|
||
(Decrease)/increase in fair value of warrant liability
|
|
(4,774,711
|
)
|
|
5,271,503
|
|
||
Stock-based compensation
|
|
1,717,380
|
|
|
1,866,279
|
|
||
Deferred income taxes benefit
|
|
(1,065,675
|
)
|
|
(25,520,615
|
)
|
||
Net realization of deferred revenue and costs due to FDA approval of oral TPOXX®
|
|
—
|
|
|
(281,950,853
|
)
|
||
Non-cash interest expense
|
|
3,363,712
|
|
|
3,363,712
|
|
||
Changes in assets and liabilities:
|
|
|
|
|
||||
Accounts receivable
|
|
(1,258,568
|
)
|
|
369,872
|
|
||
Inventory
|
|
(1,022,951
|
)
|
|
—
|
|
||
Prepaid expenses and other assets
|
|
2,189,076
|
|
|
567,042
|
|
||
Accounts payable, accrued expenses and other liabilities
|
|
(697,325
|
)
|
|
(969,951
|
)
|
||
Deferred revenue
|
|
(47,939
|
)
|
|
—
|
|
||
Net cash (used in)/provided by operating activities
|
|
(3,940,003
|
)
|
|
72,462,522
|
|
||
Cash flows from investing activities:
|
|
|
|
|
||||
Capital expenditures
|
|
(29,092
|
)
|
|
(27,863
|
)
|
||
Net cash used in investing activities
|
|
(29,092
|
)
|
|
(27,863
|
)
|
||
Cash flows from financing activities:
|
|
|
|
|
||||
Net proceeds from exercise of stock options
|
|
—
|
|
|
252,679
|
|
||
Payment of employee tax obligations for common stock tendered
|
|
(199,810
|
)
|
|
(1,708,290
|
)
|
||
Net cash used in financing activities
|
|
(199,810
|
)
|
|
(1,455,611
|
)
|
||
Net (decrease)/increase in cash, cash equivalents and restricted cash
|
|
(4,168,905
|
)
|
|
70,979,048
|
|
||
Cash, cash equivalents and restricted cash at the beginning of period
|
|
180,396,910
|
|
|
37,101,586
|
|
||
Cash, cash equivalents and restricted cash at end of period
|
|
$
|
176,228,005
|
|
|
$
|
108,080,634
|
|
|
|
|
|
|
||||
Supplemental disclosure of non-cash activities:
|
|
|
|
|
||||
Conversion of warrants to common stock
|
|
$
|
1,172,801
|
|
|
$
|
6,007,847
|
|
Issuance of common stock upon cashless exercise
|
|
$
|
118,500
|
|
|
$
|
1,582,420
|
|
|
|
As of
|
||||||
|
|
September 30, 2019
|
|
December 31, 2018
|
||||
Cash and cash equivalents
|
|
$
|
78,095,231
|
|
|
$
|
100,652,809
|
|
Restricted cash-short term
|
|
11,053,200
|
|
|
11,452,078
|
|
||
Restricted cash-long term
|
|
87,079,574
|
|
|
68,292,023
|
|
||
Cash, cash equivalents and restricted cash
|
|
$
|
176,228,005
|
|
|
$
|
180,396,910
|
|
|
|
|
|
|
||||
|
|
September 30, 2018
|
|
December 31, 2017
|
||||
Cash and cash equivalents
|
|
$
|
103,985,265
|
|
|
$
|
19,857,833
|
|
Restricted cash-short term
|
|
4,095,369
|
|
|
10,701,305
|
|
||
Restricted cash-long term
|
|
—
|
|
|
6,542,448
|
|
||
Cash, cash equivalents and restricted cash
|
|
$
|
108,080,634
|
|
|
$
|
37,101,586
|
|
|
As of
|
||||||
|
September 30, 2019
|
|
December 31, 2018
|
||||
Work in-process
|
$
|
2,970,182
|
|
|
$
|
1,950,445
|
|
Finished goods
|
960,979
|
|
|
957,765
|
|
||
Inventory
|
$
|
3,931,161
|
|
|
$
|
2,908,210
|
|
|
As of
|
||||||
|
September 30, 2019
|
|
December 31, 2018
|
||||
Leasehold improvements
|
$
|
2,420,028
|
|
|
$
|
2,420,028
|
|
Computer equipment
|
601,797
|
|
|
618,248
|
|
||
Furniture and fixtures
|
377,859
|
|
|
377,859
|
|
||
Operating lease right-of-use assets
|
2,944,932
|
|
|
—
|
|
||
|
6,344,616
|
|
|
3,416,135
|
|
||
Less - accumulated depreciation and amortization
|
(3,594,858
|
)
|
|
(3,244,861
|
)
|
||
Property, plant and equipment, net
|
$
|
2,749,758
|
|
|
$
|
171,274
|
|
|
As of
|
||||||
|
September 30, 2019
|
|
December 31, 2018
|
||||
Bonus
|
$
|
2,016,001
|
|
|
$
|
2,600,839
|
|
Deferred revenue
|
4,112,007
|
|
|
4,159,946
|
|
||
Interest payable
|
968,018
|
|
|
35,567
|
|
||
Lease liability, current portion
|
412,436
|
|
|
—
|
|
||
Research and development vendor costs
|
517,618
|
|
|
1,446,410
|
|
||
Professional fees
|
368,218
|
|
|
242,043
|
|
||
Vacation
|
297,103
|
|
|
294,794
|
|
||
Other
|
852,659
|
|
|
869,318
|
|
||
Accrued expenses and other current liabilities
|
$
|
9,544,060
|
|
|
$
|
9,648,917
|
|
•
|
Level 1 – Quoted prices for identical instruments in active markets.
|
•
|
Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.
|
•
|
Level 3 – Instruments where significant value drivers are unobservable to third parties.
|
|
Fair Value Measurements of Level 3 liability-classified warrant
|
||
Warrant liability at December 31, 2018
|
$
|
12,380,939
|
|
Decrease in fair value of warrant liability
|
(4,774,711
|
)
|
|
Exercise of warrants
|
(1,172,801
|
)
|
|
Warrant liability at September 30, 2019
|
$
|
6,433,427
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Net (loss)/income for basic earnings per share
|
$
|
(1,205,827
|
)
|
|
$
|
388,050,413
|
|
|
$
|
(2,738,542
|
)
|
|
$
|
369,416,894
|
|
Less: Change in fair value of warrants
|
981,923
|
|
|
(2,328,674
|
)
|
|
4,774,711
|
|
|
(5,271,503
|
)
|
||||
Net (loss)/income, adjusted for change in fair value of warrants for diluted earnings per share
|
$
|
(2,187,750
|
)
|
|
$
|
390,379,087
|
|
|
$
|
(7,513,253
|
)
|
|
$
|
374,688,397
|
|
Weighted-average shares
|
81,064,927
|
|
|
80,023,044
|
|
|
80,988,813
|
|
|
79,650,373
|
|
||||
Effect of potential common shares
|
1,116,931
|
|
|
2,906,432
|
|
|
1,159,520
|
|
|
3,093,854
|
|
||||
Weighted-average shares: diluted
|
82,181,858
|
|
|
82,929,476
|
|
|
82,148,333
|
|
|
82,744,227
|
|
||||
(Loss)/income per share: basic
|
$
|
(0.01
|
)
|
|
$
|
4.85
|
|
|
$
|
(0.03
|
)
|
|
$
|
4.64
|
|
(Loss)/income per share: diluted
|
$
|
(0.03
|
)
|
|
$
|
4.71
|
|
|
$
|
(0.09
|
)
|
|
$
|
4.53
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||
|
2019
|
|
2019
|
||
Stock Options
|
332,861
|
|
|
353,801
|
|
Stock-Settled Stock Appreciation Rights
|
—
|
|
|
2,227
|
|
Restricted Stock Units
|
598,793
|
|
|
545,422
|
|
|
Lease Termination liability
|
||
Balance at December 31, 2018
|
$
|
509,937
|
|
Charges (included in selling, general and administrative expenses)
|
30,764
|
|
|
Cash payments, net of sublease income
|
(294,351
|
)
|
|
Balance at September 30, 2019
|
$
|
246,350
|
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Accumulated Deficit
|
|
Other Comprehensive Income
|
|
Total Stockholders' Equity
|
|||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||
Balances at June 30, 2019
|
81,046,524
|
|
|
$
|
8,105
|
|
|
$
|
220,770,338
|
|
|
$
|
(117,323,976
|
)
|
|
$
|
—
|
|
|
$
|
103,454,467
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,205,827
|
)
|
|
—
|
|
|
(1,205,827
|
)
|
|||||
Issuance of common stock
|
53,332
|
|
|
5
|
|
|
(5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Payment of common stock tendered for employee stock-based compensation tax obligations
|
(25,576
|
)
|
|
(3
|
)
|
|
(143,217
|
)
|
|
—
|
|
|
—
|
|
|
(143,220
|
)
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
761,096
|
|
|
—
|
|
|
—
|
|
|
761,096
|
|
|||||
Balances at September 30, 2019
|
81,074,280
|
|
|
$
|
8,107
|
|
|
$
|
221,388,212
|
|
|
$
|
(118,529,803
|
)
|
|
$
|
—
|
|
|
$
|
102,866,516
|
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Accumulated Deficit
|
|
Other Comprehensive Income
|
|
Total Stockholders' Equity
|
|||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||
Balances at December 31, 2018
|
80,763,350
|
|
|
$
|
8,076
|
|
|
$
|
218,697,872
|
|
|
$
|
(115,791,261
|
)
|
|
$
|
—
|
|
|
$
|
102,914,687
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,738,542
|
)
|
|
—
|
|
|
(2,738,542
|
)
|
|||||
Issuance of common stock upon exercise of stock options
|
9,769
|
|
|
1
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights
|
121,771
|
|
|
12
|
|
|
(12
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock upon exercise of warrants
|
159,782
|
|
|
16
|
|
|
1,172,785
|
|
|
—
|
|
|
—
|
|
|
1,172,801
|
|
|||||
Issuance of common stock
|
53,332
|
|
|
5
|
|
|
(5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Payment of common stock tendered for employee stock-based compensation tax obligations
|
(33,724
|
)
|
|
(3
|
)
|
|
(199,807
|
)
|
|
—
|
|
|
—
|
|
|
(199,810
|
)
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
1,717,380
|
|
|
—
|
|
|
—
|
|
|
1,717,380
|
|
|||||
Balances at September 30, 2019
|
81,074,280
|
|
|
$
|
8,107
|
|
|
$
|
221,388,212
|
|
|
$
|
(118,529,803
|
)
|
|
$
|
—
|
|
|
$
|
102,866,516
|
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Accumulated Deficit
|
|
Other Comprehensive Income
|
|
Total Stockholders' Deficiency
|
|||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||
Balances at June 30, 2018
|
79,160,058
|
|
|
$
|
7,916
|
|
|
$
|
214,906,962
|
|
|
$
|
(556,232,608
|
)
|
|
$
|
—
|
|
|
$
|
(341,317,730
|
)
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
388,050,413
|
|
|
—
|
|
|
388,050,413
|
|
|||||
Issuance of common stock upon exercise of stock options
|
395,663
|
|
|
39
|
|
|
252,640
|
|
|
—
|
|
|
—
|
|
|
252,679
|
|
|||||
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights
|
227,287
|
|
|
23
|
|
|
(23
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock upon exercise of warrants
|
760,625
|
|
|
76
|
|
|
6,007,771
|
|
|
—
|
|
|
—
|
|
|
6,007,847
|
|
|||||
Payment of common stock tendered for employee stock-based compensation tax obligations
|
(223,098
|
)
|
|
(22
|
)
|
|
(1,695,940
|
)
|
|
—
|
|
|
—
|
|
|
(1,695,962
|
)
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
1,176,558
|
|
|
—
|
|
|
—
|
|
|
1,176,558
|
|
|||||
Balances at September 30, 2018
|
80,320,535
|
|
|
$
|
8,032
|
|
|
$
|
220,647,968
|
|
|
$
|
(168,182,195
|
)
|
|
$
|
—
|
|
|
$
|
52,473,805
|
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Accumulated Deficit
|
|
Other Comprehensive Income
|
|
Total Stockholders' Deficiency
|
|||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||
Balances at December 31, 2017
|
79,039,000
|
|
|
$
|
7,904
|
|
|
$
|
214,229,581
|
|
|
$
|
(537,375,776
|
)
|
|
$
|
—
|
|
|
$
|
(323,138,291
|
)
|
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
369,416,894
|
|
|
—
|
|
|
369,416,894
|
|
|||||
Issuance of common stock upon exercise of stock options
|
408,698
|
|
|
41
|
|
|
252,638
|
|
|
—
|
|
|
—
|
|
|
252,679
|
|
|||||
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights
|
337,084
|
|
|
33
|
|
|
(33
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Issuance of common stock upon exercise of warrants
|
760,625
|
|
|
76
|
|
|
6,007,771
|
|
|
—
|
|
|
—
|
|
|
6,007,847
|
|
|||||
Payment of common stock tendered for employee stock-based compensation tax obligations
|
(224,872
|
)
|
|
(22
|
)
|
|
(1,708,268
|
)
|
|
—
|
|
|
—
|
|
|
(1,708,290
|
)
|
|||||
Cumulative effect of accounting change
|
—
|
|
|
—
|
|
|
—
|
|
|
(223,313
|
)
|
|
—
|
|
|
(223,313
|
)
|
|||||
Stock-based compensation
|
—
|
|
|
—
|
|
|
1,866,279
|
|
|
—
|
|
|
—
|
|
|
1,866,279
|
|
|||||
Balances at September 30, 2018
|
80,320,535
|
|
|
$
|
8,032
|
|
|
$
|
220,647,968
|
|
|
$
|
(168,182,195
|
)
|
|
$
|
—
|
|
|
$
|
52,473,805
|
|
2019
|
|
$
|
97,538
|
|
2020
|
|
591,108
|
|
|
2021
|
|
600,362
|
|
|
2022
|
|
368,467
|
|
|
2023
|
|
402,078
|
|
|
Thereafter
|
|
1,387,139
|
|
|
Total undiscounted cash flows under leases
|
|
3,446,692
|
|
|
Less: Imputed interest
|
|
(515,980
|
)
|
|
Present value of lease liabilities
|
|
$
|
2,930,712
|
|
2019
|
|
$
|
541,376
|
|
2020
|
|
304,000
|
|
|
2021
|
|
304,000
|
|
|
2022
|
|
320,774
|
|
|
2023
|
|
352,000
|
|
|
Thereafter
|
|
1,197,778
|
|
|
Total
|
|
$
|
3,019,928
|
|
|
|
SIGA TECHNOLOGIES, INC.
|
||
|
|
(Registrant)
|
||
|
|
|
||
Date:
|
November 5, 2019
|
By:
|
/s/ Daniel J. Luckshire
|
|
|
|
|
Daniel J. Luckshire
|
|
|
|
|
Executive Vice President and
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
(Principal Financial Officer and
|
|
|
|
|
Principal Accounting Officer)
|
1 Year SIGA Technologies Chart |
1 Month SIGA Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions